Abstract: A method for managing metal naphthenates in produced hydrocarbons includes injecting acid and/or sour gas into produced hydrocarbons in a production well, flowline or riser, to thereby control the pH of fluids contained in the produced hydrocarbons.

Abstract: A method for managing metal naphthenates in produced hydrocarbons includes injecting acid and/or sour gas into produced hydrocarbons in a production well, flowline or riser, to thereby control the pH of fluids contained in the produced hydrocarbons.

Abstract: A method for desalting produced hydrocarbons includes injecting reduced-salinity water into produced hydrocarbons in a production well or riser, to dilute high-salinity produced water contained in the produced hydrocarbons.

Abstract: The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.

Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Abstract: This invention provides an oral veterinary pharmaceutical or nutraceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion further comprising at least one component selected from taste enhancers, odour enhancers, digestive enzymes and veterinary drugs.

Abstract: Metal naphthenate is removed from a crude hydrocarbon mixture by a process. The process includes mixing the crude hydrocarbon mixture comprising metal naphthenate with an acid in the presence of water, wherein the acid converts the metal naphthenate to naphthenic acid and metal salt; allowing the metal salt to partition into a water phase; and separating the crude heavy hydrocarbon mixture comprising naphthenic acid and the water phase comprising the metal salt.

Abstract: The present invention provides a process for removing metal naphthenate from a crude hydrocarbon mixture comprising: —mixing said crude hydrocarbon mixture (1) comprising metal naphthenate with an acid (3) in the presence of water, wherein said acid converts said metal naphthenate to naphthenic acids and metal salts; —allowing said metal salt to partition into a water phase; —separating said crude heavy hydrocarbon mixture (5) comprising naphthenic acid and said water phase (6) comprising said metal salt; and —preferably pumping said water phase comprising metal salt to a formation.

Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Abstract: This invention provides an oral veterinary pharmaceutical or nutraceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion further comprising at least one component selected from taste enhancers, odour enhancers, digestive enzymes and veterinary drugs.

Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Abstract: This invention provides a topical pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically active agent and a gelling agent, characterized in that said gelling agent comprises a fish gelatin and a polysaccharide.

Abstract: The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.

Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable shell containing a drug of abuse within an oil comprising physiologically tolerable unsaturated fatty acids.

Abstract: This invention provides an oral veterinary pharmaceutical or nutraceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion further comprising at least one component selected from taste enhancers, odour enhancers, digestive enzymes and veterinary drugs.

Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.

Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a statin within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, one or both of the oil phase and the water phase whereof comprises a physiologically tolerable omega-3 acid ester.

Abstract: The invention relates to soft gelatin capsules containing at least one pharmaceutical, wherein the capsule shell includes carrageenan and cold water fish gelatin or a mixture of cold fish gelatin and warm fish gelatin.